Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Yuflyma® (adalimumab-aaty) – New biosimilar approval
May 23, 2023 - The FDA approved Celltrion’s Yuflyma (adalimumab-aaty) citrate-free, high concentration (100 mg/mL) injection, biosimilar to AbbVie’s Humira® (adalimumab).
